

**Olmesartan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Olmesartan Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil 13106-054

Telephone : 908-740-4000

Emergency telephone : 55 19 3758 2000

E-mail address : EHSDATASTEWARD@msd.com

Telefax : 908-735-1496

**Recommended use of the chemical and restrictions on use**Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Reproductive toxicity : Category 1A

**GHS label elements in accordance with ABNT NBR 14725 Standard**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.

Precautionary Statements :  
**Prevention:**  
P201 Obtain special instructions before use.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
**Storage:**  
P405 Store locked up.

## Olmesartan Formulation

Version 2.2      Revision Date: 09/13/2019      SDS Number: 717973-00009      Date of last issue: 24.04.2019  
 Date of first issue: 01.06.2016

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Olmesartan	144689-63-4	Acute toxicity (Oral), Category 4 Eye irritation, Category 2B Reproductive toxicity, Category 1A	>= 5 -< 10
Cellulose	9004-34-6		>= 5 -< 10

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)

## Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

Unsuitable extinguishing media	:	Dry chemical None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.

## Olmesartan Formulation

Version 2.2      Revision Date: 09/13/2019      SDS Number: 717973-00009      Date of last issue: 24.04.2019  
 Date of first issue: 01.06.2016

- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Avoid contact with eyes.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

## Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

### Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

**Olmesartan Formulation**

Version 2.2      Revision Date: 09/13/2019      SDS Number: 717973-00009      Date of last issue: 24.04.2019  
Date of first issue: 01.06.2016

---

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg

---

**Olmesartan Formulation**

Version 2.2      Revision Date: 09/13/2019      SDS Number: 717973-00009      Date of last issue: 24.04.2019  
Date of first issue: 01.06.2016

---

Method: Calculation method

**Components:****Olmesartan:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
LD50 (Mouse): > 2.000 mg/kg  
LD50 (Dog): > 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Remarks : No data available

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Species : Rabbit  
Result : Moderate eye irritation  
Method : Draize Test

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Olmesartan Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 24.04.2019  
2.2            09/13/2019            717973-00009      Date of first issue: 01.06.2016

---

**Components:****Olmesartan:**

Routes of exposure            : Skin contact  
Remarks                        : No data available

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Olmesartan:**

Genotoxicity in vitro            : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Mutagenicity (in vitro mammalian cytogenetic test)  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster lung cells  
Result: positive  
  
Test Type: Mouse Lymphoma  
Result: negative  
  
Genotoxicity in vivo            : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative  
  
Germ cell mutagenicity -  
Assessment                        : Weight of evidence does not support classification as a germ  
cell mutagen.

**Cellulose:**

Genotoxicity in vitro            : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
  
Genotoxicity in vivo            : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Olmesartan:**

Species                            : Rat



## Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

Species : Mouse  
 Application Route : Oral  
 Exposure time : 6 Months  
 Result : negative

**Cellulose:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks  
 Result : negative

**Reproductive toxicity**

May damage the unborn child.

**Components:****Olmesartan:**

Effects on fertility : Test Type: Fertility  
 Species: Rat  
 Application Route: Oral  
 Fertility: NOAEL: 1.000 mg/kg body weight  
 Result: No effects on fertility.

Effects on fetal development : Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Dose: 1000 milligram per kilogram  
 Result: No teratogenic effects.

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Dose: 1 milligram per kilogram  
 Result: No teratogenic effects.

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL:  $\geq$  1,6 mg/kg body weight  
 Symptoms: Malformations were observed., Reduced body weight  
 Result: Effects on postnatal development.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat

## Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### Olmesartan:

Species : Rat  
NOAEL : 2.000 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Remarks : No significant adverse effects were reported

##### Cellulose:

Species : Rat  
NOAEL :  $\geq 9.000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Olmesartan:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension  
Remarks: May cause harm to the unborn child.  
Based on Human Evidence

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)):  $> 100$  mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Olmesartan Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 24.04.2019  
2.2                09/13/2019                717973-00009            Date of first issue: 01.06.2016

---

**Persistence and degradability****Components:****Cellulose:**

Biodegradability                                :    Result: Readily biodegradable.

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues                                :    Dispose of in accordance with local regulations.  
Contaminated packaging                                :    Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****ANTT**

Not regulated as a dangerous good

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)                                :    Not applicable

Brazil. Ordinance No. 1274 on the control and                                :    Not applicable

---

**Olmesartan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

monitoring of chemicals.

**International Regulations**

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**SECTION 16. OTHER INFORMATION****Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB

## Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
2.2	09/13/2019	717973-00009	Date of first issue: 01.06.2016

---

- Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8